Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Biomarkers of systemic inflammation/nutritional status have been associated with outcomes in advanced-stage non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). However, most of them were not tested in cohorts of patients treated with ICIs in combination with chemotherapy (CT) (ICI + CT) or with CT alone, making it impossible to discriminate a predictive from a prognostic effect. We conducted a single-center retrospective study to search for associations between various baseline biomarkers/scores that reflected the systemic inflammation/nutritional status (Lung Immune Prognostic Index, Modified Lung Immune Prognostic Index, Scottish Inflammatory Prognostic Score, Advanced Lung Cancer Inflammation Index, EPSILoN, Prognostic Nutritional Index, Systemic Immune-Inflammation Index, Gustave Roussy Immune Score, Royal Marsden Hospital Prognostic Score, Lung Immuno-oncology Prognostic Score 3, Lung Immuno-oncology Prognostic Score 4, score published by Holtzman et al., and Glasgow Prognostic Score) and outcomes in metastatic NSCLC treated in a first-line setting either with ICI in monotherapy (cohort 1; n = 75), ICI + CT (cohort 2; n = 56), or CT alone (cohort 3; n = 221). In the three cohorts, the biomarkers/scores were moderately associated with overall survival (OS) and progression-free survival (PFS). Their prognostic performance was relatively poor, with a maximum c-index of 0.66. None of them was specific to ICIs and could help to choose the best treatment modality. The systemic inflammation/nutritional status, associated with outcomes independently of the treatment, is therefore prognostic but not predictive in metastatic NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 One-year overall survival (OS) and six-month progression-free survival (PFS) in the three cohorts, according to the scores based on biomarkers of systemic inflammation/nutritional status, analyzed as binary variables (high or low level). The numbers indicated in the squares represent the Kaplan–Meier estimation of the one-year OS or the six-month PFS. Abbreviations: ALI—Advanced Lung Cancer Inflammation Index [28], CT—chemotherapy alone, EPSILoN [32], GPS—Glasgow Prognostic Score [46], GRIm—Gustave Roussy Immune Score [33], Holtzman—score described by Holtzman et al. [36], ICI—ICI in monotherapy, ICI + CT—ICI in combination with chemotherapy, LIPI—Lung Immune Prognostic Index [29], LIPS-3—Lung Immuno-oncology Prognostic Score 3 [35], LIPS-4—Lung Immuno-oncology Prognostic Score 4 [35], mLIPI—Modified Lung Immune Prognostic Index [30], PNI—Prognostic Nutritional Index [43], RMH—Royal Marsden Hospital Prognostic Score [45], SII—Systemic Immune-Inflammation Index [44], and SIPS—Scottish Inflammatory Prognostic Score [31].](https://figures.cochat.ai/paper-figures/4f77b0282ffa4b3093f33cab52694c60/systemic-inflammation-nutritional-status-scores-are-prognostic-but-not-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · cited 2×
“After systemic inflammation has been proposed as a hallmark of cancer based on the fact that it promotes tumor development and dissemination [23,24], various studies have investigated the role of biomarkers of systemic inflammation in response to ICIs in patients suffering from advanced-stage NSCLC [25].”
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 1×
“Moreover, only 35% of the NSCLCs in cohorts 1 and 2 had a PD-L1 TPS <50%, which could be disturbing given that this proportion is generally estimated between 72 and 77% in the literature [63,64].”
Cited by
Ancel, J., Dormoy, V., Nawrocki‐Raby, B., Dalstein, V., Durlach, A., Dewolf, M., Gilles, C., Polette, M., & Deslée, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1171649 · Cited by 40
“Their results supported that systemic inflammation/nutritional status could be associated with the outcomes independently of the treatment, and were therefore prognostic but not predictive (59).”
ResultYamaguchi, O., Kaira, K., Imai, H., Mouri, A., Shiono, A., Miura, Y., Hashimoto, K., Kobayashi, K., & Kagamu, H. (2023) · Oncology · doi:10.1159/000534169 · Cited by 21
Nguyen, C. T. T., Van, T. N. K., & Huong, P. T. (2024) · Cancer Control · doi:10.1177/10732748241285474 · Cited by 26
Ito, K., Hashimoto, K., Kaira, K., Yamaguchi, O., Mouri, A., Shiono, A., Miura, Y., Kobayashi, K., Imai, H., Kuji, I., et al. (2024) · Oncology Letters · doi:10.3892/ol.2024.14243 · Cited by 11
Lee, K. H., Lee, J.-S., Sugawara, S., Kang, J., Kim, H. R., Inui, N., Hida, T., Yoshida, T., Tanaka, H., Yang, C., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108109 · Cited by 16
Metadata
- Authors
- Mahiat, C., Bihin, B., Duplaquet, F., Stanciu Pop, C., Dupont, M., Vander Borght, T., Rondelet, B., Vanderick, J., André, B., Pirard, L., & Ocak, S.
- Affiliations
- UCLouvain (BE)
- CHU Dinant Godinne UCL Namur (BE)
- Pathology Department, CHU UCL Namur (Godinne Site), UCLouvain, Avenue Docteur G. Thérasse 1, 5530 Yvoir, Belgium
- Radiology Division, CHU UCL Namur (Godinne Site), UCLouvain, Avenue Docteur G. Thérasse 1, 5530 Yvoir, Belgium
- Nuclear Medicine Division, CHU UCL Namur (Godinne Site), UCLouvain, Avenue Docteur G. Thérasse 1, 5530 Yvoir, Belgium
- Thoracic Surgery Department, CHU UCL Namur (Godinne Site), UCLouvain, Avenue Docteur G. Thérasse 1, 5530 Yvoir, Belgium
- Corresponding author
- Ocak, Sebahat
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-02-10
- Volume
- 24
- Issue
- 4
- Pages
- 3618
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9966997
- OpenAlex
- W4320493683
- Cited by
- 23
- References
- 73
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 6 · 2023: 3
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- metastatic non-small cell lung cancer, immune checkpoint inhibitors, systemic inflammation, nutritional status, prognostic factors, prognostic score, first-line therapy, chemotherapy, overall survival, progression-free survival, immune-related adverse events
- MeSH terms
- Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Humans, Inflammation, Lung Neoplasms, Nutritional Status, Prognosis, Retrospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors. https://app.cochat.ai/papers/10.3390/ijms24043618
- The paper
- Mahiat, C., Bihin, B., Duplaquet, F., Stanciu Pop, C., Dupont, M., Vander Borght, T., Rondelet, B., Vanderick, J., André, B., Pirard, L., & Ocak, S. (2023). Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043618
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.